Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

Publié en January 2019 LANCET

A high probability of short-range interactions between fibrocytes and CD8 T cells in chronic obstructive pulmonary disease (COPD) lungs

Previous publication

Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study

Next publication